Imatinib Mesylate, also known by brand names Gleevec and Glivec, is a medication used to treat various cancers and blood cell disorders. Here's a breakdown of its key aspects:
Conditions treated:
- Chronic Myeloid Leukemia (CML) with specific genetic mutations
- Gastrointestinal Stromal Tumors (GIST)
- Certain types of acute lymphoblastic leukemia (ALL)
- Myelodysplastic/myeloproliferative diseases (MDS/MPD)
- Aggressive systemic mastocytosis
- Hypereosinophilic syndrome
- Dermatofibrosarcoma protuberans (DFSP) in specific cases
How it works:
- Imatinib Mesylate belongs to a class of drugs called tyrosine kinase inhibitors (TKIs).
- It targets and blocks specific proteins (tyrosine kinases) that are crucial for the growth and survival of cancer cells.
- In CML, for instance, it inhibits the BCR-ABL protein, which fuels the uncontrolled growth of leukemia cells.
Dosage and administration:
- Imatinib Mesylate comes in tablet form and is taken orally, usually once or twice daily with a meal.
- The specific dosage depends on the type and stage of cancer being treated.
Important points to remember:
- Imatinib Mesylate is a powerful medication and should only be taken under a doctor's supervision.
- It can cause side effects, including nausea, fatigue, muscle cramps, and fluid retention.
- It's crucial to discuss any potential side effects and interactinos with other medications with your doctor before starting treatment.
Additional Resources:
- You can find more detailed information about Imatinib Mesylate on the website of the National Cancer Institute https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055302/
- MedlinePlus also has a page on Imatinib with patient-friendly information https://www.webmd.com/drugs/2/drug-20983/imatinib-oral/details
External Links
Imatinib Mesylate